CSPC Pharmaceutical : VOLUNTARY ANNOUNCEMENT - "DULOXETINE HYDROCHLORIDE ENTERIC CAPSULES" OBTAINS DRUG REGISTRATION APPROVAL

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CSPC Pharmaceutical Group Limited

石 藥 集 團 有 限 公 司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT

"DULOXETINE HYDROCHLORIDE ENTERIC CAPSULES"

OBTAINS DRUG REGISTRATION APPROVAL

The board of directors (the "Board") of CSPC Pharmaceutical Group Limited (the "Company", together with its subsidiaries, the "Group") is pleased to announce that the "Duloxetine Hydrochloride Enteric Capsules (20mg, 30mg, 60mg)" (the "Product") developed by CSPC Ouyi Pharmaceutical Co., Ltd.*（石藥集團歐意藥業有限公司）, a subsidiary of the Company, has obtained drug registration approval granted by the National Medical Products Administration of the People's Republic of China, being the second generic drug of this type passing the consistency of quality and efficacy evaluation in China.

Duloxetine hydrochloride is a nervous system drug indicated for the treatment of major depressive disorder, generalized anxiety disorder and chronic musculoskeletal pain.

The approval of the Product further enriches the Group's product portfolio and enhances the Group's development in the nervous system field.

By order of the Board

CSPC Pharmaceutical Group Limited

Cai Dongchen

Chairman

Hong Kong, 27 July 2020

As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LU Hua, Dr. LI Chunlei, Dr. WANG Qingxi and Mr. CHAK Kin Man as executive directors; Mr. LEE Ka Sze, Carmelo as non- executive director; and Mr. CHAN Siu Keung, Leonard, Mr. WANG Bo, Prof. LO Yuk Lam, Dr. YU Jinming and Mr. CHEN Chuan as independent non-executive directors.

• For identification purpose only